Quantinno Capital Management LP Increases Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Quantinno Capital Management LP raised its stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 24.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 8,312 shares of the company’s stock after buying an additional 1,622 shares during the period. Quantinno Capital Management LP’s holdings in BeOne Medicines were worth $2,469,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Capital International Investors raised its holdings in shares of BeOne Medicines by 1.3% during the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after acquiring an additional 67,808 shares during the period. Siren L.L.C. grew its holdings in shares of BeOne Medicines by 1.4% in the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after purchasing an additional 7,010 shares during the period. Morgan Stanley increased its position in BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after purchasing an additional 84,367 shares during the last quarter. Bank of America Corp DE increased its position in BeOne Medicines by 23.5% during the third quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock worth $117,629,000 after purchasing an additional 65,763 shares during the last quarter. Finally, Candriam S.C.A. raised its stake in BeOne Medicines by 31.7% during the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after purchasing an additional 62,470 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $348.27 on Monday. The firm’s 50-day moving average is $296.52 and its two-hundred day moving average is $308.69. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The stock has a market capitalization of $38.21 billion, a P/E ratio of 61.32 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. On average, sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ONC. Guggenheim boosted their target price on shares of BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a report on Thursday. JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company started coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Finally, Leerink Partners raised their target price on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and a consensus target price of $400.00.

Insider Buying and Selling

In other BeOne Medicines news, CEO John Oyler sold 145,861 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the sale, the chief executive officer owned 8,122 shares of the company’s stock, valued at $2,484,925.90. The trade was a 94.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the transaction, the chief operating officer owned 40 shares in the company, valued at $10,774.80. This trade represents a 97.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 345,561 shares of company stock valued at $105,625,947 in the last ninety days. 6.19% of the stock is currently owned by corporate insiders.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.